Serum phosphate and phosphate-regulatory hormones in COPD patients

[1]  P. Andreopoulou,et al.  Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type , 2016, Osteoporosis International.

[2]  S. Judd,et al.  Associations of Fibroblast Growth Factor-23 with Markers of Inflammation, Insulin Resistance and Obesity in Adults , 2015, PloS one.

[3]  W. März,et al.  Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study. , 2014, Atherosclerosis.

[4]  J. Chudek,et al.  Fibroblast growth factor 23 (FGF23) and early chronic kidney disease in the elderly. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  H. Olauson,et al.  FGF23 and Klotho in chronic kidney disease , 2013, Current opinion in nephrology and hypertension.

[6]  Huiliang Xie,et al.  Fibroblast growth factor 23 and Inflammation in CKD. , 2012, American Society of Nephrology. Clinical Journal.

[7]  Jiang He,et al.  Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. , 2011, JAMA.

[8]  R. Farah,et al.  Hypophosphatemia as a prognostic value in acute exacerbation of COPD , 2013, The clinical respiratory journal.

[9]  M. Ohnishi,et al.  Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  H. Milionis,et al.  Medication-induced hypophosphatemia: a review. , 2010, QJM : monthly journal of the Association of Physicians.

[11]  L. Schurgers,et al.  The Associations of Fibroblast Growth Factor 23 and Uncarboxylated Matrix Gla Protein With Mortality in Coronary Artery Disease: The Heart and Soul Study , 2010, Annals of Internal Medicine.

[12]  H. Jüppner,et al.  Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23. , 2010, Annual review of medicine.

[13]  M. Mohammadi,et al.  FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. , 2009, American journal of physiology. Renal physiology.

[14]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[15]  C. Mathers,et al.  Projections of Global Mortality and Burden of Disease from 2002 to 2030 , 2006, PLoS medicine.

[16]  M. Razzaque,et al.  Premature aging‐like phenotype in fibroblast growth factor 23 null mice is a vitamin D‐mediated process , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  Y. Takeuchi,et al.  FGF‐23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  K. Miyamoto,et al.  Human Fibroblast Growth Factor-23 Mutants Suppress Na+-dependent Phosphate Co-transport Activity and 1α,25-Dihydroxyvitamin D3 Production* , 2003, The Journal of Biological Chemistry.

[19]  J. Sunyer,et al.  Epidemiology of chronic obstructive pulmonary disease. , 2001, The European respiratory journal.

[20]  E. Fiaccadori,et al.  Hypophosphatemia and phosphorus depletion in respiratory and peripheral muscles of patients with respiratory failure due to COPD. , 1994, Chest.

[21]  E. Fiaccadori,et al.  Hypophosphatemia in course of chronic obstructive pulmonary disease. Prevalence, mechanisms, and relationships with skeletal muscle phosphorus content. , 1990, Chest.

[22]  Brenda R. Hemmelgarn,et al.  Notice , 2012, Kidney International Supplements.

[23]  M. Elsammak,et al.  Fibroblast Growth Factor-23 and Hypophosphatemia in Chronic Obstructive Pulmonary Disease Patients , 2011 .